These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
162 related articles for article (PubMed ID: 39169342)
1. Prognostic factors for thyroid-stimulating immunoglobulin normalization in moderate-to-severe Graves' orbitopathy: a 36-month longitudinal study. Park J; Son Y; Kim J; Kim S; Choi HY BMC Ophthalmol; 2024 Aug; 24(1):361. PubMed ID: 39169342 [TBL] [Abstract][Full Text] [Related]
2. Clinical performance of a novel and rapid bioassay for detection of thyroid-stimulating immunoglobulins in Graves' orbitopathy patients: a comparison with two commonly used immunoassays. Hötte GJ; de Bie M; de Keizer ROB; Kolijn PM; Drexhage RC; Veenbergen S; Versnel MA; van Hagen PM; Paridaens D; Dik WA Front Endocrinol (Lausanne); 2024; 15():1469179. PubMed ID: 39398334 [TBL] [Abstract][Full Text] [Related]
3. Clinical Association of Thyroid Stimulating Hormone Receptor Antibody Levels with Disease Severity in the Chronic Inactive Stage of Graves' Orbitopathy. Woo YJ; Jang SY; Lim TH; Yoon JS Korean J Ophthalmol; 2015 Aug; 29(4):213-9. PubMed ID: 26240504 [TBL] [Abstract][Full Text] [Related]
4. Thyroid stimulating immunoglobulin concentration is associated with disease activity and predicts response to treatment with intravenous methylprednisolone in patients with Graves' orbitopathy. Hötte GJ; Kolijn PM; de Bie M; de Keizer ROB; Medici M; van der Weerd K; van Hagen PM; Paridaens D; Dik WA Front Endocrinol (Lausanne); 2024; 15():1340415. PubMed ID: 38577576 [TBL] [Abstract][Full Text] [Related]
5. Predicting the Development of Orbitopathy in Graves Thyroidopathy Patients: The Potential Role of TSI Testing. Takakura A; Kirkeby K; Earle K; Silkiss RZ Ophthalmic Plast Reconstr Surg; 2015; 31(5):369-72. PubMed ID: 25585304 [TBL] [Abstract][Full Text] [Related]
6. Prognostic significance of thyroid-stimulating hormone receptor antibodies in moderate-to-severe graves' orbitopathy. Park J; Kim J; Kim SS; Choi HY Front Endocrinol (Lausanne); 2023; 14():1153312. PubMed ID: 37223049 [TBL] [Abstract][Full Text] [Related]
7. A novel thyroid stimulating immunoglobulin bioassay is a functional indicator of activity and severity of Graves' orbitopathy. Lytton SD; Ponto KA; Kanitz M; Matheis N; Kohn LD; Kahaly GJ J Clin Endocrinol Metab; 2010 May; 95(5):2123-31. PubMed ID: 20237164 [TBL] [Abstract][Full Text] [Related]
8. Glucocorticoid-induced adrenal insufficiency after therapy with intravenous methylprednisolone in patients with moderate-to-severe and active Graves' orbitopathy: assessment with a low-dose corticotropin test. Pelewicz K; Miśkiewicz P J Endocrinol Invest; 2024 Aug; 47(8):1987-1994. PubMed ID: 38310626 [TBL] [Abstract][Full Text] [Related]
9. Clinical relevance of thyroid-stimulating immunoglobulins in graves' ophthalmopathy. Ponto KA; Kanitz M; Olivo PD; Pitz S; Pfeiffer N; Kahaly GJ Ophthalmology; 2011 Nov; 118(11):2279-85. PubMed ID: 21684605 [TBL] [Abstract][Full Text] [Related]
10. Association of clinical course with thyroid-stimulating immunoglobulin in Graves' ophthalmopathy in Mongolians. Bayarmunkh O; Ganbold C; Das S; Davaatseren U; Minjuurdorj NE; Jav S PLoS One; 2022; 17(11):e0277055. PubMed ID: 36395261 [TBL] [Abstract][Full Text] [Related]
11. Clinical efficacy of thyroid-stimulating immunoglobulin detection for diagnosing Graves' disease and predictors of responsiveness to methimazole. Liu K; Fu Y; Li T; Liu S; Chen D; Zhao C; Shi Y; Cai Y; Yang T; Zheng X Clin Biochem; 2021 Nov; 97():34-40. PubMed ID: 34331946 [TBL] [Abstract][Full Text] [Related]
12. Serum concentrations of HGF and IL-8 in patients with active Graves' orbitopathy before and after methylprednisolone therapy. Nowak M; Siemińska L; Karpe J; Marek B; Kos-Kudła B; Kajdaniuk D J Endocrinol Invest; 2016 Jan; 39(1):63-72. PubMed ID: 26062519 [TBL] [Abstract][Full Text] [Related]
13. Longitudinal correlation of thyroid-stimulating immunoglobulin with clinical activity of disease in thyroid-associated orbitopathy. Dragan LR; Seiff SR; Lee DC Ophthalmic Plast Reconstr Surg; 2006; 22(1):13-9. PubMed ID: 16418659 [TBL] [Abstract][Full Text] [Related]
14. Epidemiology of thyroid-stimulating immunoglobulin in recent-onset symptomatic thyroid eye disease. Lai KKH; Aljufairi FMAA; Sebastian JU; Wei Y; Jia R; Chan KKW; Au EYL; Lee ACH; Ng CM; Yuen HKL; Yip WWK; Young AL; Cheng GPM; Tham CCY; Pang CP; Chong KKL Eur Thyroid J; 2024 Aug; 13(4):. PubMed ID: 38847819 [TBL] [Abstract][Full Text] [Related]
15. Comparison Between Thyroid Stimulating Immunoglobulin and TSH-Receptor Antibodies in the Management of Graves' Orbitopathy. Khamisi S; Lundqvist M; Engström BE; Larsson A; Karlsson FA; Ljunggren Ö Exp Clin Endocrinol Diabetes; 2023 Apr; 131(4):236-241. PubMed ID: 36706788 [TBL] [Abstract][Full Text] [Related]
16. Relevance of TSH-receptor antibody levels in predicting disease course in Graves' orbitopathy: comparison of the third-generation TBII assay and Mc4-TSI bioassay. Jang SY; Shin DY; Lee EJ; Lee SY; Yoon JS Eye (Lond); 2013 Aug; 27(8):964-71. PubMed ID: 23743527 [TBL] [Abstract][Full Text] [Related]
17. Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves' orbitopathy: a randomized controlled study. Salvi M; Vannucchi G; Currò N; Campi I; Covelli D; Dazzi D; Simonetta S; Guastella C; Pignataro L; Avignone S; Beck-Peccoz P J Clin Endocrinol Metab; 2015 Feb; 100(2):422-31. PubMed ID: 25494967 [TBL] [Abstract][Full Text] [Related]
18. Clinical characteristics of Graves' orbitopathy in patients showing discrepancy between levels from TBII assays and TSI bioassay. Jang SY; Shin DY; Lee EJ; Yoon JS Clin Endocrinol (Oxf); 2014 Apr; 80(4):591-7. PubMed ID: 24033537 [TBL] [Abstract][Full Text] [Related]
19. Diagnostic accuracy of Immulite® TSI immunoassay for thyroid-associated orbitopathy in patients with recently diagnosed Graves' hyperthyroidism. Thia B; McGuinness MB; Ebeling PR; Khong JJ Int Ophthalmol; 2022 Mar; 42(3):863-870. PubMed ID: 34613563 [TBL] [Abstract][Full Text] [Related]
20. The combination of absent thyroid peroxidase antibodies and high thyroid-stimulating immunoglobulin levels in Graves' disease identifies a group at markedly increased risk of ophthalmopathy. Khoo DH; Ho SC; Seah LL; Fong KS; Tai ES; Chee SP; Eng PH; Aw SE; Fok AC Thyroid; 1999 Dec; 9(12):1175-80. PubMed ID: 10646655 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]